Search results
25 mar 2022 · This review discusses the mechanisms of resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) and the emerging novel agents targeting them. It covers EGFR-dependent and EGFR-independent resistance, as well as MET-, HER2-, and HER3-directed therapies in development.
The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer.
31 maj 2021 · Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are standard of care in the first-line (1L) setting for patients with metastatic non–small cell lung cancer (mNSCLC) with activating EGFR mutations.
23 wrz 2024 · The first-line treatment for patients with EGFR-mutant lung cancer is likely to evolve over the coming years, as recent data have demonstrated that treatment strategies combining either chemotherapy or amivantamab with an EGFR TKI may be superior to osimertinib monotherapy in the first-line setting. 15, 16 While these studies have shown ...
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022 May;33 (5):466-487. doi: 10.1016/j.annonc.2022.02.003. Epub 2022 Feb 14. Authors.
14 lut 2022 · The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer.
What are the treatment options for someone with EGFR-positive cancer? EGFR in lung cancer has been widely studied and therefore several treatment options exist. As researchers learn more, suggested treatment protocols may change.
